Psychiatry · AntipsychoticRegulatory Approvalregulatorymid-term

Aurobindo Pharma's Lurasidone Hydrochloride ANDA208045 Receives AP Status

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Aurobindo Pharma25 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/19/2026, 12:32:48 AM

Assessment confidence: 73% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's Abbreviated Approval status for Aurobindo Pharma's Lurasidone Hydrochloride indicates a significant shift in the competitive landscape for antipsychotic medications. This approval could lead to increased market competition, impacting pricing and market share for existing products. Regulatory context from FDA (FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (16 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for antipsychotic medications. The strongest clinical anchor is Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN (ClinicalTrials.gov), sponsor/company relevance (novartis). In Psychiatry · Antipsychotic, 8 regulatory and 7 competitive items passed relevance filtering for Aurobindo Pharma.

Competitive Pressure

The most relevant competitive pressure comes from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) (Roche) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217).

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL) (FDA). Entity match (lurasidone hydrochloride); Regulatory pathway relevance (nda). The approval signifies a successful regulatory pathway for Aurobindo, which may encourage similar applications from other companies, impacting future regulatory submissions in this therapeutic area.

Key Risks

Elevated medium regulatory exposure for Aurobindo Pharma could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community) could weigh on Aurobindo Pharma through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The entry of Aurobindo Pharma into the Lurasidone market may pressure pricing strategies and affect the revenue of current market players, potentially altering market dynamics.
Upside for Aurobindo Pharma may improve if Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this approval on market share and pricing strategies for antipsychotic medications.

What Would Change This Assessment

This becomes more urgent if Monitor for the launch timeline and any potential market entry strategies from Aurobindo Pharma.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (lurasidone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ALFUZOSIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants W
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Novartishigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts BLA for IMMGOLIS (GOLIMUMAB-SLDI) by Accord Biopharma
Humanexa Signalsmedium relevance
Moderate corpus alignment

Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma
Lurasidone Hydrochloride

Commercial impact

medium

The entry of Aurobindo Pharma into the Lurasidone market may pressure pricing strategies and affect the revenue of current market players, potentially altering market dynamics.

Regulatory impact

medium

The approval signifies a successful regulatory pathway for Aurobindo, which may encourage similar applications from other companies, impacting future regulatory submissions in this therapeutic area.

What to watch

Monitor for the launch timeline and any potential market entry strategies from Aurobindo Pharma.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.